Interleukin-32: Frenemy in cancer?

키워드

참고문헌 (75)

1. Zitvogel L, "Cancer despite immunosurveillance : immunoselection and immunosubversion", Nat Rev Immunol, 6, pp.715~727 (2006)
2. Galon J, "Type, density, and location of immune cells within human colorectal tumors predict clinical outcome", Science, 313, pp.1960~1964 (2006)
3. Mosmann TR, "Two types of murine helper T cell clone. I. definition according to profiles of lymphokine activities and secreted proteins", J Immunol, 136, pp.2348~2357 (1986)
4. Sakaguchi S, "FOXP3+ regulatory T cells in the human immune system", Nat Rev Immunol, 10, pp.490~500 (2010)
5. O'Sullivan KE, "The role of inflammation in cancer of the esophagus", Expert Rev Gastroenterol Hepatol, 8, pp.749~760 (2014)
6. Tosello-Trampont A, "Immunoregulatory role of NK Cells in tissue inflammation and regeneration", Front Immunol, 8, pp.301~ (2017)
7. Yadav D, "The epidemiology of pancreatitis and pancreatic cancer", Gastroenterology, 144, pp.1252~1261 (2013)
8. Freeman HJ, "Colorectal cancer risk in Crohn's disease", World J Gastroenterol, 14, pp.1810~1811 (2008)
9. Warren JR, "Gastric pathology associated with Helicobacter pylori", Gastroenterol Clin North Am, 29, pp.705~751 (2000)
10. Noto JM, "Helicobacter pylori : an overview", Methods Mol Biol, 921, pp.7~10 (2012)
11. Sakitani K, "Role of interleukin-32 in Helicobacter pylori-induced gastric inflammation", Infect Immun, 80, pp.3795~3803 (2012)
12. 서은희, "Detection of Expressed IL-32 in Human Stomach Cancer Using ELISA and Immunostaining", Journal of Microbiology and Biotechnology, 18(9), pp.1606~1612 (2008), 한국미생물·생명공학회
13. Khawar MB, "IL-32 : A Novel Pluripotent inflammatory interleukin, towards gastric inflammation, gastric cancer, and chronic rhino sinusitis", Mediators Inflamm, 2016, pp.8413768~ (2016)
14. Yan H, "Role of interleukin-32in cancer biology", Oncol Lett, 16, pp.41~47 (2018)
15. Heinhuis B, "Inflammationdependent secretion and splicing of IL-32γ in rheumatoid arthritis", Proc Natl Acad Sci U S A, 108, pp.4962~4967 (2011)
16. Heinhuis B, "Alternatively spliced isoforms of IL-32 differentially influence cell death pathways in cancer cell lines", Carcinogenesis, 37, pp.197~205 (2016)
17. Sloot YJE SJ, "Insights into the role of IL-32 in cancer", Semin Immunol, 38, pp.24~32 (2018)
18. Wang S, "IL-32 promotes breast cancer cell growth and invasiveness", Oncol Lett, 9, pp.305~307 (2015)
19. Taguchi A, "Interleukin-8promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan", Cancer Epidemiol Biomarkers Prev, 14, pp.2487~2493 (2005)
20. Wang YM, "Association of genetic polymorphisms of interleukins with gastric cancer and precancerous gastric lesions in a high-risk Chinese population", Tumour Biol, 37, pp.2233~2242 (2016)
21. Tsai CY, "Interleukin-32increases human gastric cancer cell invasion associated with tumor progression and metastasis", Clin Cancer Res, 20, pp.2276~2288 (2014)
22. Ishigami S, "IL-32expression is an independent prognostic marker for gastric cancer", Med Oncol, 30, pp.472~ (2013)
23. Erturk K, "Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer", Tumour Biol, 37, pp.405~412 (2006)
24. Chang WJ, "Inflammation-related factors predicting prognosis of gastric cancer", World J Gastroenterol, 20, pp.4586~4596 (2014)
25. Nishida A, "Interleukin-32 expression in the pancreas", J Biol Chem, 284, pp.17868~17876 (2009)
26. van Hogezand RA, "Malignancies in inflammatory bowel disease: fact or fiction?", Scand J Gastroenterol Suppl, pp.48~53 (2002)
27. Yun HM, "IL-32alpha suppresses colorectal cancer development via TNFR1-mediated death signaling", Oncotarget, 6, pp.9061~9072 (2015)
28. Tanaka T, "A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate", Cancer Sci, 94, pp.965~973 (2003)
29. Okayasu I, "A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice", Gastroenterology, 98, pp.694~702 (1990)
30. Yang Y, "Dysregulation of over-expressed IL-32 in colorectal cancer induces metastasis", World J Surg Oncol, 13, pp.146~ (2015)
31. Khawar MB, "IL-32 : a recently identified anti-inflammatory variant of IL-32 and its preventive role in various disorders and tumor suppressor activity", Am J Transl Res, 9, pp.4726~4737 (2017)
32. Catalán V, "IL-32-induced inflammation constitutes a link between obesity and colon cancer", Oncoimmunology, 6, pp.e1328338~ (2017)
33. Sherman M, "AASLD single-topic research conference on hepatocellular carcinoma : Conference proceedings", Hepatology, 40, pp.1465~1473 (2004)
34. Xu H, "TIMP-1 expression induced by IL-32 is mediated through activation of AP-1signal pathway", Int Immunopharmacol, 38, pp.233~237 (2016)
35. Kim SH, "Interleukin-32 : a cytokine and inducer of TNFalpha", Immunity, 22, pp.131~142 (2005)
36. Kudo M, "Oxidative stress induced interleukin-32 mRNA expression in human bronchial epithelial cells", Respir Res, 13, pp.19~ (2012)
37. Dinarello CA, "IL-32, a novel cytokine with a possible role in disease", Ann Rheum Dis, 65(Suppl 3), pp.iii61~iii64 (2006)
38. Pan X, "Interleukin-32 expression induced by hepatitis B virus protein X is mediated through activation of NF-kappaB", Mol Immunol, 48, pp.1573~1577 (2011)
39. Moschen AR, "Interleukin-32 : a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis", Hepatology, 53, pp.1819~1829 (2011)
40. Kang YH, "Dysregulation of overexpressed IL-32alpha in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-kappaB and Bcl-2", Cancer Lett, 318, pp.226~233 (2012)
41. Zhao WB, "Overexpression of interleukin-32α promotes invasion by modulating VEGF in hepatocellular carcinoma", Oncol Rep, 39, pp.1155~1162 (2018)
42. Iliaz R, "Role of several cytokines and adhesion molecules in the diagnosis and prediction of survival of hepatocellular carcinoma", Arab J Gastroenterol, 17, pp.164~167 (2016)
43. Kim DH, "Intracellular interleukin-32gamma mediates antiviral activity of cytokines against hepatitis B virus", Nat Commun, 9, pp.3284~ (2018)
44. Sato M, "A translational view of the molecular pathogenesis of lung cancer", J Thorac Oncol, 2, pp.327~343 (2007)
45. Zeng Q, "Interleukin-32contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression", Cytokine, 65, pp.24~32 (2013)
46. Sorrentino C, "Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype", Am J Respir Crit Care Med, 180, pp.769~779 (2009)
47. Wang Y, "Polymorphisms and expression of IL-32 : impact on genetic susceptibility and clinical outcome of lung cancer", Biomarkers, 22, pp.165~170 (2017)
48. Yun J, "IL-32 gamma reduces lung tumor development through upregulation of TIMP-3overexpression and hypomethylation", Cell Death Dis, 9, pp.306~ (2018)
49. Park JS, "Interleukin-32beta stimulates migration of MDA-MB-231 and MCF-7cells via the VEGF-STAT3 signaling pathway", Cell Oncol (Dordr), 36, pp.493~503 (2013)
50. Park JS, "Hypoxia-induced IL-32beta increases glycolysis in breast cancer cells", Cancer Lett, 356, pp.800~808 (2014)
51. Ainscough JS, "Dendritic cell IL-1alpha and IL-1beta are polyubiquitinated and degraded by the proteasome", J Biol Chem, 289, pp.35582~35592 (2014)
52. Yong HJ, "Von Hippel-Lindau regulates interleukin-32beta stability in ovarian cancer cells", Oncotarget, 8, pp.69833~69846 (2017)
53. Ternette N, "Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens", Proteomics, 18, pp.e1700465~ (2018)
54. Lee S, "Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene", Immunology, 132, pp.410~420 (2010)
55. Sojung Lee, "The Biflavonoid Amentoflavone Induces Apoptosis via Suppressing E7 Expression, Cell Cycle Arrest at Sub-G1 Phase, and Mitochondria-Emanated Intrinsic Pathways in Human Cervical Cancer Cells", Journal of Medicinal Food, 14(7), pp.808~816 (2011), 한국식품영양과학회
56. Goda C, "Involvement of IL-32 in activation-induced cell death in T cells", Int Immunol, 18, pp.233~240 (2006)
57. Zhang F, "Phospholipase A2-activating protein(PLAA)enhances cisplatin-induced apoptosis in HeLa cells", Cell Signal, 21, pp.1085~1099 (2009)
58. Cui Y, "Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma", Oncol Lett, 11, pp.693~698 (2016)
59. Yamac D, "Cyclooxygenase-2 expression and its association with angiogenesis, Helicobacter pylori, and clinicopathologic characteristics of gastric carcinoma", Pathol Res Pract, 204, pp.527~536 (2008)
60. Konturek PC, "Helicobacter pylori, gastrin and cyclooxygenases in gastric cancer", J Physiol Pharmacol, 51, pp.737~749 (2000)
61. Lee S, "Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene", Immunology, 132, pp.410~420 (2011)
62. van Kester MS, "A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides", J Invest Dermatol, 132, pp.2050~2059 (2012)
63. Suga H, "The role of IL-32 in cutaneous T-cell lymphoma", J Invest Dermatol, 134, pp.1428~1435 (2013)
64. Cheon S, "Overexpression of IL-32alpha increases natural killer cell-mediated killing through up-regulation of Fas and UL16-binding protein 2(ULBP2)expression in human chronic myeloid leukemia cells", J Biol Chem, 286, pp.12049~12055 (2011)
65. Raulet DH, "Roles of the NKG2D immunoreceptor and its ligands", Nat Rev Immunol, 3, pp.781~790 (2003)
66. Jamieson AM, "The role of the NKG2D immunoreceptor in immune cell activation and natural killing", Immunity, 17, pp.19~29 (2002)
67. Park MH, "Interleukin-32enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3", Immunology, 135, pp.63~72 (2011)
68. Smyth MJ, "Tumor necrosis factor-related apoptosis-inducing ligand(TRAIL)contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis", J Exp Med, 193, pp.661~670 (2001)
69. Screpanti V, "Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells", Mol Immunol, 42, pp.495~499 (2005)
70. Yun HM, "Antitumor activity of IL-32beta through the activation of lymphocytes, and the inactivation of NF-kappaB and STAT3 signals", Cell Death Dis, 4, pp.e640~ (2013)
71. Oh JH, "IL-32gamma inhibits cancer cell growth through inactivation of NF-kappaB and STAT3 signals", Oncogene, 30, pp.3345~3359 (2011)
72. Qu Y, "Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin(IL)-32", Cancer Gene Ther, 18, pp.663~673 (2011)
73. Ohmatsu H, "IL-32induces indoleamine 2, 3-dioxygenase+CD1c+ dendritic cells and indoleamine 2, 3-dioxygenase+CD163+ macrophages : Relevance to mycosis fungoides progression", Oncoimmunology, 6, pp.e1181237~ (2017)
74. Chang CJ, "Oct4-related cytokine effects regulate tumorigenic properties of colorectal cancer cells", Biochem Biophys Res Commun, 415, pp.245~251 (2011)
75. Moldenhauer A, "Interleukin 32 promotes hematopoietic progenitor expansion and attenuates bone marrow cytotoxicity", Eur J Immunol, 41, pp.1774~1786 (2011)

관련 논문AI추천